EUCTR2015-000894-11-ITActive, not recruitingPhase 1
Vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer: a phase II study - COREVAX-1
ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS0 sites19 target enrollmentStarted: December 20, 2017Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 19
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •- Histologically confirmed stage IV colorectal cancer surgically treated with radical intent. - The autologous surgical specimen must have been collected and sent to the Somatic Cell Therapy Lab of IRST IRCCS and must fulfil all the acceptance criteria prescribed by the GMP procedures. - The patient must be disease-free. - Age >18 years. - ECOG performance status 0 or 1. - Acceptable organ function.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 12
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 7
Exclusion Criteria
- •- Residual disease after surgery. - Relapse within 6 months since primary treatment of stage I-III colorectal cancer. - Surgery more than 60 days before study enrolment. - History of other neoplastic diseases. - History of congenital or acquired immunodeficiency. - Any positivity for the serologic markers of HBV (including at least anti-HBs antibodies and anti-HBc antibodies), HCV, HIV or Treponema pallidum. - Pregnancy or nursing. - Patients undergone surgery after preoperatory chemotherapy with a fluoropyrimidine plus oxaliplatin, unless they are not candidate for postoperatory chemotherapy with the same schedule in the opinion of the Investigator (e.g. for unacceptable toxicity) or refuse completion of the perioperatory treatment. - Participation in another clinical trial. - Any active inflammatory or autoimmune disease. - Any contraindication to leukaphaeresis.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alfa in patients with metastatic melanoma: a randomized proof-of-principle” phase II study.metastatic melanomaMedDRA version: 15.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001410-41-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
Active, not recruiting
Phase 1
Vaccination with Autologous Dendritic cells loaded with Autologous Tumour homogenate in Glioblastoma: a phase II StudyMedDRA version: 20.0Level: PTClassification code: 10018336Term: Glioblastoma Class: 100000004864GlioblastomaCTIS2024-512493-98-00Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.28
Active, not recruiting
Phase 1
Vaccination with Autologous Dendritic cells loaded with Autologous Tumour homogenate in Glioblastoma: a phase II StudyglioblastomaMedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003755-15-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS28
Active, not recruiting
Phase 1
Vaccination with dendritic cells pulsed with autologous tumorhomogenate in combination with HD-IL2 and immunomodulating radiotherapy in metastatic RCC: a phase II trial (RENALVax-2)metastatic renal cancerMedDRA version: 20.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000556-14-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS37
Active, not recruiting
Phase 1
Dendritic cells as autologous vaccine in patients with chronic myeloid leukemiaEUCTR2006-006962-41-DECharité Universitätsmedizin Berlin30